Aim This review aims to summarize and discuss some of the most relevant clinical trials in
epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. Data …

Heart failure (HF) is a common condition with an increasing prevalence. Despite a variety of
evidence-based treatments for patients with HF with reduced ejection fraction, morbidity and …

Despite the availability of efficacious pharmacological treatments, hypertension remains the
leading global cause of death and disability, 1 and rates of blood pressure (BP) control are …

Even though it has been more than a decade since renal denervation (RDN) was first used
to treat hypertension and an intense effort on researching this therapy has been made, it is …

Background Renal denervation is optimised when guided by knowledge of nerve
distribution. Aims We aimed to assess sympathetic nerve distribution along the renal …

Despite the availability of safe and effective antihypertensive drugs, blood pressure (BP)
control to guideline-recommended target values is poor. Several device-based therapies …

Renal denervation (RDN) is currently confronted with the considerable heterogeneity of
different post-procedural blood pressure responses. The challenges predominantly arise …

Background: Renal denervation (RDN) lowers blood pressure (BP), but BP response is
variable in individual patients. We investigated whether measures of pulsatile …

Background The accurate selection of patients likely to respond to renal denervation (RDN)
is crucial for optimizing treatment outcomes in patients with hypertension. This systematic …

Sympathetic overactivation is one of the main contributors to development and progress of
hypertension. Renal denervation (RDN) has been evidenced by series of clinical trials for its …